Frontier Clinical Research LLC

1. Pfizer Inc. $2,950,372 101 payments
2. AbbVie, Inc. $2,458,658 671 payments
3. Genentech, Inc. $1,823,585 281 payments
4. Allergan Inc. $986,814 275 payments
5. Eli Lilly and Company $942,026 49 payments
6. GlaxoSmithKline, LLC. $693,880 240 payments
7. Kowa Research Institute, Inc. $266,048 66 payments
8. Chiesi USA, Inc. $177,382 34 payments
9. Adaptive Biotechnologies Corporation $170,267 4 payments
10. Janssen Research & Development, LLC $166,967 40 payments

1. A Phase 3 Multicenter Placebocontrolled Randomized Observerblinded Trial to Evaluate the Efficacy Safety Tolerability Immunogenicity and Lot Consistency of A 6Valent Ospabased Lyme Disease Vaccine in Healthy Participants 5 Years of Age $2,950,372 101 payments
2. Roche Cancer Screening Collection Study $1,226,895 192 payments
3. A Phase 3 Study to Compare the Efficacy and Safety of Gepotidacin With $462,556 148 payments
4. Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine $456,131 88 payments
5. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $360,753 51 payments
6. A phase IIIB surveillance study of susceptibility to baloxavir marboxil $257,559 32 payments
7. Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $247,324 97 payments
8. Transmission Study Household $241,743 31 payments
9. A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity Or Overweight With and Without Type 2 Diabetes: J2a-Mc-Gzp1, J2a-Mc-Gzp2 $228,064 2 payments
10. K-877-302 $197,350 42 payments

1. Other $170,267 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.